AIM ImmunoTech wins U.S. patent covering Ampligen-Keytruda combo cancer therapy through 2039 - AIM News | RalliesAIM ImmunoTech wins U.S. patent covering Ampligen-Keytruda combo cancer therapy through 2039
A
AIM• New patent extends Ampligen cancer combination protection
- AIM ImmunoTech won a new U.S. patent covering Ampligen (rintatolimod) used with Merck’s Keytruda (pembrolizumab) to treat cancer.
- Patent term runs to Dec. 20, 2039, extending the company’s oncology intellectual property around Ampligen combination therapy.
- Broadest claim covers Ampligen-Keytruda treatment across cancers when the combination outperforms either drug alone.
- The company also cited other Ampligen checkpoint-combination patents, including a U.S. patent expiring Aug. 9, 2039.
